Inmune Stock Valuation

INMB
 Stock
  

USD 8.77  0.07  0.79%   

Do you wonder what the value of Inmune Bio is? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Inmune Bio, is its stock price multiplied by the total number of shares outstanding, calculating Inmune Bio's enterprise value requires a different approach. It uses Inmune Bio's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Inmune Bio Enterprise Value is projected to increase significantly based on the last few years of reporting. The past year's Enterprise Value was at 112.06 Million. The current year Tangible Asset Value is expected to grow to about 90 M, whereas Free Cash Flow is forecasted to decline to (29.3 M).
Inmune Bio retains a regular Real Value of $15.63 per share. The prevalent price of the firm is $8.77. At this time, the firm appears to be undervalued. Our model calculates the value of Inmune Bio from evaluating the firm fundamentals such as Return On Equity of (51.00) %, shares owned by insiders of 34.96 %, and Return On Asset of (25.92) % as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage taking in undervalued assets and trading overvalued assets since, at some point, asset prices and their ongoing real values will come together.
  
Refresh
Inmune Bio Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Inmune Bio's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

Inmune Most Recent Valuation Data

Price Book
1.94
Enterprise Value
95.3 M
Enterprise Value Ebitda
-3.07
Price Sales
462.9
Enterprise Value Revenue
280.44
Undervalued
Today 8.77
Please note that Inmune Bio's price fluctuation is somewhat reliable at this time. Calculation of the real value of Inmune Bio is based on 3 months time horizon. Increasing Inmune Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Inmune Bio is useful when determining the fair value of the Inmune stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Inmune Bio. Since Inmune Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Inmune Stock. However, Inmune Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
15.63
Real Value
21.96
Upside
Estimating the potential upside or downside of Inmune Bio helps investors to forecast how Inmune stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Inmune Bio more accurately as focusing exclusively on Inmune Bio's fundamentals will not take into account other important factors:
Earnings
Estimates (1)
LowProjected EPSHigh
-1.91-1.91-1.91
Details
Hype
Prediction
LowEstimated ValueHigh
2.338.6614.99
Details
Naive
Forecast
LowNext ValueHigh
2.839.1615.49
Details
2 Analysts
Consensus
LowTarget PriceHigh
32.0037.0042.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Inmune Bio's intrinsic value based on its ongoing forecasts of Inmune Bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Inmune Bio's closest peers. When choosing an evaluation method for Inmune Bio, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Inmune Valuation Drivers Correlation

Many accounts on the financial statements of Inmune Bio are highly interrelated and sometimes correlated. Consequently, when conducting Inmune's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Inmune
Click cells to compare fundamentals

Inmune Valuation Trend

Knowing Inmune Bio's actual value is paramount for traders to make sound investment determinations. Inmune Bio's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Inmune Bio's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Inmune Bio's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Inmune Market Cap

Inmune Bio is currently regarded as number one stock in market capitalization category among related companies. Market capitalization of Biotechnology industry is currently estimated at about 74.73 Billion. Inmune Bio adds roughly 156.49 Million in market capitalization claiming only tiny portion of stocks in Biotechnology industry.
Capitalization  Valuation  Total debt  Workforce  Revenue

Inmune Bio Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Inmune Bio's current stock value. Our valuation model uses many indicators to compare Inmune Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inmune Bio competition to find correlations between indicators driving Inmune Bio's intrinsic value. More Info.
Inmune Bio is currently regarded as number one stock in price to sales category among related companies. It is currently regarded as number one stock in price to book category among related companies . The ratio of Price to Sales to Price to Book for Inmune Bio is about  488.45 . The current year Price to Book Value is expected to grow to 2.72. Comparative valuation analysis is a catch-all model that can be used if you cannot value Inmune Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Inmune Bio's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inmune Bio's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Inmune Bio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Inmune Bio and how it compares across the competition.

About Inmune Bio Valuation

The equity valuation mechanism determines the current worth of Inmune Bio on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Inmune Bio. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Inmune Bio based exclusively on its fundamental and basic technical indicators. By analyzing Inmune Bio's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Inmune Bio's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Inmune Bio. We calculate exposure to Inmune Bio's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Inmune Bio's related companies.
Last ReportedProjected for 2022
Gross Profit181 K150.8 K
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Inmune Bio Quarterly Enterprise Value

90.83 Million

Share

Inmune Bio Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Inmune Bio does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio18.42
Revenue Growth1,381.80%
Enterprise Value To Revenue413.01

Inmune Bio Current Valuation Indicators

Valuation refers to the process of determining the present value of Inmune Bio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Inmune we look at many different elements of the entity such as Inmune's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Inmune Bio's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Inmune Bio's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Inmune Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Inmune Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Inmune Bio's worth.
Please see Risk vs Return Analysis. Note that the Inmune Bio information on this page should be used as a complementary analysis to other Inmune Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Inmune Stock analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Is Inmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmune Bio. If investors know Inmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
157.4 M
Quarterly Revenue Growth YOY
39.75
Return On Assets
-0.24
Return On Equity
-0.47
The market value of Inmune Bio is measured differently than its book value, which is the value of Inmune that is recorded on the company's balance sheet. Investors also form their own opinion of Inmune Bio's value that differs from its market value or its book value, called intrinsic value, which is Inmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmune Bio's market value can be influenced by many factors that don't directly affect Inmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Inmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.